{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:20:42Z","timestamp":1793686842487,"version":"4.5.1"},"reference-count":224,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01196-w","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T02:02:34Z","timestamp":1645236154000},"page":"691-710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases"],"prefix":"10.1016","volume":"19","author":[{"given":"Panos","family":"Stathopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-1134","authenticated-orcid":false,"given":"Marinos C.","family":"Dalakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01196-w_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2006.03.005","article-title":"B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target","volume":"112","author":"Dalakas","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1007\/s13311-022-01196-w_bib2","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Invited article: inhibition of B cell functions: implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s13311-015-0402-6","article-title":"Anti-B-cell therapies in autoimmune neurological diseases: rationale and efficacy trials","volume":"13","author":"Alexopoulos","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-022-01196-w_bib6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s11882-014-0434-8","article-title":"B cell biology: an overview","volume":"14","author":"Eibel","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1007\/s13311-022-01196-w_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/80816","article-title":"Antibody regulation of B cell development","volume":"1","author":"Meffre","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"10.1007\/s13311-022-01196-w_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0889-857X(03)00109-1","article-title":"B-cell biology","volume":"30","author":"Weinstein","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1007\/s13311-022-01196-w_bib11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.immuni.2011.03.025","article-title":"Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity","volume":"34","author":"Kitano","year":"2011","journal-title":"Immunity"},{"key":"10.1007\/s13311-022-01196-w_bib12","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.4049\/jimmunol.177.11.7723","article-title":"Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor","volume":"177","author":"O'Connor","year":"2006","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nri3802","article-title":"Memory B cells","volume":"15","author":"Kurosaki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","article-title":"Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis","volume":"298","author":"Lebrun","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib17","doi-asserted-by":"crossref","unstructured":"Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra30.","DOI":"10.1126\/scitranslmed.3005166"},{"key":"10.1007\/s13311-022-01196-w_bib18","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01196-w_bib19","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01196-w_bib20","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.4049\/jimmunol.0801859","article-title":"Novel human transitional B cell populations revealed by B cell depletion therapy","volume":"182","author":"Palanichamy","year":"2009","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib21","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment","volume":"58","author":"Roll","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01196-w_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-022-01196-w_bib23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1007\/s13311-022-01196-w_bib24","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-022-01196-w_bib25","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-022-01196-w_bib26","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1021\/bi051685o","article-title":"Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor)","volume":"45","author":"Cachero","year":"2006","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-022-01196-w_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0092-8674(02)00631-1","article-title":"Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands","volume":"108","author":"Liu","year":"2002","journal-title":"Cell"},{"key":"10.1007\/s13311-022-01196-w_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-3083.2007.02049.x","article-title":"B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome","volume":"67","author":"Lavie","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib29","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01196-w_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2008.06.005","article-title":"Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells","volume":"44","author":"Suzuki","year":"2008","journal-title":"Cytokine"},{"key":"10.1007\/s13311-022-01196-w_bib31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2007-09-110874","article-title":"TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts","volume":"111","author":"Bossen","year":"2008","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01196-w_bib32","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-022-01196-w_bib33","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1523\/JNEUROSCI.5040-08.2009","article-title":"Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor","volume":"29","author":"Zhang","year":"2009","journal-title":"The Journal of neuroscience : the official journal of the Society for Neuroscience"},{"key":"10.1007\/s13311-022-01196-w_bib34","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1084\/jem.20042309","article-title":"Identification of proteoglycans as the APRIL-specific binding partners","volume":"201","author":"Ingold","year":"2005","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-022-01196-w_bib35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4049\/jimmunol.1001120","article-title":"The structure of the TNFRSF13C promoter enables differential expression of BAFF-R during B cell ontogeny and terminal differentiation","volume":"185","author":"Mihalcik","year":"2010","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0960-9822(01)00481-X","article-title":"Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency","volume":"11","author":"Yan","year":"2001","journal-title":"Current biology : CB"},{"key":"10.1007\/s13311-022-01196-w_bib37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.humimm.2012.05.001","article-title":"A novel compound heterozygous TACI mutation in an autosomal recessive common variable immunodeficiency (CVID) family","volume":"73","author":"Lougaris","year":"2012","journal-title":"Hum Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-022-01196-w_bib39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaci.2012.10.029","article-title":"TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes","volume":"131","author":"Martinez-Gallo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib40","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-022-01196-w_bib41","doi-asserted-by":"crossref","unstructured":"Hoffmann FS, Kuhn P-H, Laurent SA, et al. The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity. J.I. 2015;194:542\u2013552.","DOI":"10.4049\/jimmunol.1402070"},{"key":"10.1007\/s13311-022-01196-w_bib42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.immuni.2008.03.017","article-title":"A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses","volume":"28","author":"Yanaba","year":"2008","journal-title":"Immunity"},{"key":"10.1007\/s13311-022-01196-w_bib43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"10.1007\/s13311-022-01196-w_bib44","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jaci.2013.01.014","article-title":"IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses","volume":"131","author":"van de Veen","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib45","doi-asserted-by":"crossref","unstructured":"Mauri C, Menon M. The expanding family of regulatory B cells. Int Immunol. 2015.","DOI":"10.1093\/intimm\/dxv038"},{"key":"10.1007\/s13311-022-01196-w_bib46","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.160.7.3555","article-title":"IgE versus IgG4 production can be differentially regulated by IL-10","volume":"160","author":"Jeannin","year":"1998","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib47","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib48","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2010-07-294249","article-title":"Characterization of a rare IL-10\u2013competent B-cell subset in humans that parallels mouse regulatory B10 cells","volume":"117","author":"Iwata","year":"2011","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01196-w_bib49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01196-w_bib50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cell.2018.11.035","article-title":"Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10","volume":"176","author":"Rojas","year":"2019","journal-title":"Cell"},{"key":"10.1007\/s13311-022-01196-w_bib51","doi-asserted-by":"crossref","unstructured":"Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF\u2013producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7.","DOI":"10.1126\/scitranslmed.aab4176"},{"key":"10.1007\/s13311-022-01196-w_bib52","doi-asserted-by":"crossref","unstructured":"Miyagaki T, Fujimoto M, Sato S, Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. Int Immunol. 2015.","DOI":"10.1093\/intimm\/dxv026"},{"key":"10.1007\/s13311-022-01196-w_bib53","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/eji.200939633","article-title":"Tolerance checkpoints in B-cell development: Johnny B good","volume":"39","author":"Tussiwand","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib54","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1073\/pnas.1522730113","article-title":"Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins","volume":"113","author":"Br\u00e4ndle","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01196-w_bib55","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm1714","article-title":"Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis","volume":"14","author":"Obermeier","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01196-w_bib56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ana.24190","article-title":"Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis: IgM Oligoclonal Bands in PPMS","volume":"76","author":"Villar","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-022-01196-w_bib58","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.21524","article-title":"Immunoglobulins and complement in postmortem multiple sclerosis tissue","volume":"65","author":"Barnett","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib60","doi-asserted-by":"crossref","unstructured":"Kap YS, van Driel N, Blezer E, et al. Late B cell depletion with a human anti-human CD20 IgG1\u03ba monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets. J.I. 2010;185:3990\u20134003.","DOI":"10.4049\/jimmunol.1001393"},{"key":"10.1007\/s13311-022-01196-w_bib61","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/awh486","article-title":"Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis","volume":"128","author":"Cepok","year":"2005","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01196-w_bib62","doi-asserted-by":"crossref","unstructured":"Willis SN, Stathopoulos P, Chastre A, et al. Investigating the antigen specificity of multiple sclerosis central nervous system-derived immunoglobulins. Front Immunol. 2015;6.","DOI":"10.3389\/fimmu.2015.00600"},{"key":"10.1007\/s13311-022-01196-w_bib63","doi-asserted-by":"crossref","unstructured":"Stern JNH, Yaari G, Vander Heiden JA, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Science Translational Medicine 2014;6:248ra107\u2013248ra107.","DOI":"10.1126\/scitranslmed.3008879"},{"key":"10.1007\/s13311-022-01196-w_bib64","doi-asserted-by":"crossref","unstructured":"Palanichamy A, Apeltsin L, Kuo TC, et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med. 2014;6.","DOI":"10.1126\/scitranslmed.3008930"},{"key":"10.1007\/s13311-022-01196-w_bib65","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/eji.201040516","article-title":"Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein","volume":"40","author":"Harp","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neulet.2009.08.010","article-title":"Memory and naive B-cell subsets in patients with multiple sclerosis","volume":"464","author":"Niino","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-022-01196-w_bib67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2011.08.019","article-title":"Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced na\u00efve\/memory Breg ratio during a relapse but not in remission","volume":"239","author":"Knippenberg","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib68","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clim.2014.09.011","article-title":"Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis","volume":"155","author":"Michel","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jneuroim.2010.02.012","article-title":"Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis","volume":"221","author":"Hirotani","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib70","doi-asserted-by":"crossref","unstructured":"Guerrier T, Labalette M, Launay D, et al. Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurol Neuroimmunol Neuroinflamm. 2018;5:e431.","DOI":"10.1212\/NXI.0000000000000431"},{"key":"10.1007\/s13311-022-01196-w_bib71","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib72","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12974-016-0785-2","article-title":"BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset","volume":"14","author":"Puthenparampil","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-022-01196-w_bib74","unstructured":"Braun T, Juenemann M, Dornes K, et al. BAFF serum and CSF levels in patients with multiple sclerosis and infectious nervous system diseases. Int J Neurosci. 2020;1\u20136."},{"key":"10.1007\/s13311-022-01196-w_bib75","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458511398887","article-title":"Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid","volume":"17","author":"Ragheb","year":"2011","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2016.05.013","article-title":"BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset","volume":"297","author":"Puthenparampil","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib77","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnen\/64.2.129","article-title":"Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis","volume":"64","author":"Satoh","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib78","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1038\/s41598-021-82346-6","article-title":"B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF","volume":"11","author":"Bakhuraysah","year":"2021","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-022-01196-w_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.mcn.2014.07.001","article-title":"LOTUS suppresses axon growth inhibition by blocking interaction between Nogo receptor-1 and all four types of its ligand","volume":"61","author":"Kurihara","year":"2014","journal-title":"Mol Cell Neurosci"},{"key":"10.1007\/s13311-022-01196-w_bib80","doi-asserted-by":"crossref","unstructured":"Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J.I. 2014;193:580\u2013586.","DOI":"10.4049\/jimmunol.1400118"},{"key":"10.1007\/s13311-022-01196-w_bib81","doi-asserted-by":"crossref","unstructured":"Schuh E, Berer K, Mulazzani M, et al. Features of human CD3 + CD20 + T cells. J.I. 2016;197:1111\u20131117.","DOI":"10.4049\/jimmunol.1600089"},{"key":"10.1007\/s13311-022-01196-w_bib82","doi-asserted-by":"crossref","first-page":"25800","DOI":"10.1073\/pnas.1915309116","article-title":"Anti-CD20 therapy depletes activated myelin-specific CD8 + T cells in multiple sclerosis","volume":"116","author":"Sabatino","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01196-w_bib83","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis","volume":"62","author":"Monson","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib84","doi-asserted-by":"crossref","unstructured":"Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67.","DOI":"10.1001\/archneurol.2010.99"},{"key":"10.1007\/s13311-022-01196-w_bib85","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology"},{"key":"10.1007\/s13311-022-01196-w_bib86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458508098268","article-title":"Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders","volume":"15","author":"Petereit","year":"2009","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib87","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib88","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib89","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib91","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib92","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib93","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib94","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib95","doi-asserted-by":"crossref","unstructured":"Juto A, Fink K, Al Nimer F, et al. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord. 2020;37:101468.","DOI":"10.1016\/j.msard.2019.101468"},{"key":"10.1007\/s13311-022-01196-w_bib96","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jneuroim.2014.08.617","article-title":"Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis","volume":"276","author":"Studer","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib97","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1352458511418631","article-title":"Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis","volume":"18","author":"Nielsen","year":"2012","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib98","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/2055217316672100","article-title":"Experience with long-term rituximab use in a multiple sclerosis clinic","volume":"2","author":"Barra","year":"2016","journal-title":"Multiple Sclerosis Journal - Experimental, Translational and Clinical"},{"key":"10.1007\/s13311-022-01196-w_bib101","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1212\/WNL.0000000000006916","article-title":"Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis","volume":"92","author":"Honce","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s42466-020-00074-0","article-title":"Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosis","volume":"2","author":"Schwake","year":"2020","journal-title":"Neurol Res Pract"},{"key":"10.1007\/s13311-022-01196-w_bib103","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van VOLLENHOVEN","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-022-01196-w_bib104","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01196-w_bib105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib106","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib107","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib108","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib109","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1474-4422(14)70050-X","article-title":"Trial and error in clinical studies: lessons from ATAMS","volume":"13","author":"L\u00fchder","year":"2014","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib110","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-022-01196-w_bib111","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-022-01196-w_bib112","doi-asserted-by":"crossref","unstructured":"Stathopoulos P, Chastre A, Waters P, et al. Autoantibodies against neurologic antigens in nonneurologic autoimmunity. J.I. 2019;202:2210\u20132219.","DOI":"10.4049\/jimmunol.1801295"},{"key":"10.1007\/s13311-022-01196-w_bib113","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00401-018-1950-8","article-title":"Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat","volume":"137","author":"Hillebrand","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01196-w_bib114","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/acn3.418","article-title":"CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder","volume":"4","author":"Kowarik","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib116","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib117","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archneurol.2011.62","article-title":"Neuromyelitis optica with extensive active brain involvement: an autopsy study","volume":"68","author":"Almekhlafi","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib118","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-022-01196-w_bib119","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1352458516672015","article-title":"Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood\u2013brain barrier disruption","volume":"23","author":"Uchida","year":"2017","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jneuroim.2017.01.006","article-title":"Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder","volume":"305","author":"Kimura","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib121","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2017.03.006","article-title":"Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica","volume":"469","author":"Uzawa","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1007\/s13311-022-01196-w_bib122","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/1352458510380416","article-title":"Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population","volume":"16","author":"Vaknin-Dembinsky","year":"2010","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib123","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1352458512454771","article-title":"Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis","volume":"19","author":"Quan","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib124","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib125","doi-asserted-by":"crossref","unstructured":"Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2015.","DOI":"10.1177\/1352458515594042"},{"key":"10.1007\/s13311-022-01196-w_bib126","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib127","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","article-title":"Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders","volume":"324","author":"Ip","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01196-w_bib129","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0883073810381445","article-title":"Efficacy and safety of rituximab in pediatric neuromyelitis optica","volume":"26","author":"Mahmood","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib131","doi-asserted-by":"crossref","unstructured":"Zografou C, Vakrakou AG, Stathopoulos P. Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front Immunol. 2021;12:686466.","DOI":"10.3389\/fimmu.2021.686466"},{"key":"10.1007\/s13311-022-01196-w_bib132","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2013.02.024","article-title":"Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases","volume":"328","author":"Gredler","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01196-w_bib133","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib134","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01196-w_bib135","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib136","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"The Lancet"},{"key":"10.1007\/s13311-022-01196-w_bib137","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib138","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib139","doi-asserted-by":"crossref","unstructured":"Rigal J, Pugnet G, Ciron J, et al. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series. Mult Scler Relat Disord. 2020;46:102483.","DOI":"10.1016\/j.msard.2020.102483"},{"key":"10.1007\/s13311-022-01196-w_bib140","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib141","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib142","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein: MOG antibody pathogenicity","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis","volume":"289","author":"Horellou","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib144","doi-asserted-by":"crossref","unstructured":"Kothur K, Wienholt L, Tantsis EM, et al. B Cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination. PLoS One. 2016;11:e0149411. [Meinl E, editor].","DOI":"10.1371\/journal.pone.0149411"},{"key":"10.1007\/s13311-022-01196-w_bib145","doi-asserted-by":"crossref","unstructured":"in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius S, Ruprecht K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.","DOI":"10.1186\/s12974-016-0718-0"},{"key":"10.1007\/s13311-022-01196-w_bib146","doi-asserted-by":"crossref","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251.","DOI":"10.1016\/j.msard.2020.102251"},{"key":"10.1007\/s13311-022-01196-w_bib147","doi-asserted-by":"crossref","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, et al. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. Mult Scler Relat Disord. 2021;48:102696.","DOI":"10.1016\/j.msard.2020.102696"},{"key":"10.1007\/s13311-022-01196-w_bib148","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib149","doi-asserted-by":"crossref","unstructured":"Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378;840\u2013851. [Ropper AH, editor].","DOI":"10.1056\/NEJMra1708712"},{"key":"10.1007\/s13311-022-01196-w_bib150","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/brain\/aww208","article-title":"Human cerebrospinal fluid monoclonal N -methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis","volume":"139","author":"Kreye","year":"2016","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01196-w_bib151","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib152","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ana.25666","article-title":"Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability","volume":"87","author":"Kornau","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib153","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.pedneo.2018.10.006","article-title":"Immunotherapy for anti-NMDA receptor encephalitis: experience from a single center in Taiwan","volume":"60","author":"Kong","year":"2019","journal-title":"Pediatr Neonatol"},{"key":"10.1007\/s13311-022-01196-w_bib154","doi-asserted-by":"crossref","unstructured":"Dou X, Li D, Wu Y, et al. Efficacy and safety of rituximab in Chinese children with refractory anti-NMDAR encephalitis. Front Neurol. 2020;11:606923.","DOI":"10.3389\/fneur.2020.606923"},{"key":"10.1007\/s13311-022-01196-w_bib155","doi-asserted-by":"crossref","unstructured":"Lee W-J, Lee S-T, Shin Y-W, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics. 2020.","DOI":"10.1007\/s13311-020-00921-7"},{"key":"10.1007\/s13311-022-01196-w_bib156","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib157","doi-asserted-by":"crossref","unstructured":"Ratuszny D, Skripuletz T, Wegner F, et al. Case report: daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis. Front Neurol. 2020;11:602102.","DOI":"10.3389\/fneur.2020.602102"},{"key":"10.1007\/s13311-022-01196-w_bib158","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib159","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 2015;1852:658\u201366.","DOI":"10.1016\/j.bbadis.2014.06.013"},{"key":"10.1007\/s13311-022-01196-w_bib160","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1471-4159.2010.07029.x","article-title":"Antibodies against ganglioside complexes in Guillain-Barre syndrome and related disorders","volume":"116","author":"Kusunoki","year":"2011","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01196-w_bib161","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain : a journal of neurology"},{"key":"10.1007\/s13311-022-01196-w_bib162","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barre syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib163","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib164","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib165","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.30.8.864","article-title":"CSF \u2018monoclonal' bands in chronic relapsing polyneuropathy","volume":"30","author":"Dalakas","year":"1980","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib166","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrneurol.2014.260","article-title":"Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders","volume":"11","author":"Stathopoulos","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib167","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/brain\/aww062","article-title":"Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects","volume":"139","author":"Manso","year":"2016","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01196-w_bib168","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1172\/JCI124694","article-title":"Anti\u2013neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo","volume":"129","author":"Manso","year":"2019","journal-title":"J Clin Investig"},{"key":"10.1007\/s13311-022-01196-w_bib169","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01196-w_bib170","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJM199003083221002","article-title":"Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy","volume":"322","author":"Monaco","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01196-w_bib171","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.20364","article-title":"IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy","volume":"57","author":"Lombardi","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib172","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2007.10.025","article-title":"Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG","volume":"193","author":"Ilyas","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib173","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-022-01196-w_bib174","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1007\/s00415-020-10041-z","article-title":"Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera","volume":"267","author":"Delmont","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib175","doi-asserted-by":"crossref","unstructured":"Querol L, Rojas-Garc\u00eda R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149.","DOI":"10.1212\/NXI.0000000000000149"},{"key":"10.1007\/s13311-022-01196-w_bib176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.02.009","article-title":"Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment","volume":"281","author":"Campagnolo","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib177","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"Leger","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib178","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features","volume":"89","author":"Svahn","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01196-w_bib179","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI58743","article-title":"Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity","volume":"122","author":"Maurer","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1007\/s13311-022-01196-w_bib180","doi-asserted-by":"crossref","unstructured":"Rakocevic G, Martinez-Outschoorn U, Dalakas MC. Obinutuzumab, a potent anti\u2013B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. Neurol Neuroimmunol Neuroinflamm 2018;5:e460.","DOI":"10.1212\/NXI.0000000000000460"},{"key":"10.1007\/s13311-022-01196-w_bib181","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ene.13838","article-title":"Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy","volume":"26","author":"Briani","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib182","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.57.5.780","article-title":"Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies","volume":"57","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib183","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Fujii M, Li M, et al. The clinical spectrum of anti-GAD antibodypositive patients with stiff-person syndrome. Neurology. 2000;55(10):1531\u20135.","DOI":"10.1212\/WNL.55.10.1531"},{"key":"10.1007\/s13311-022-01196-w_bib184","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonz\u00e1lez","year":"2014","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01196-w_bib185","doi-asserted-by":"crossref","unstructured":"Rizzi M, Knoth R, Hampe CS, et al. Long-lived plasma cells and memory B Cells produce pathogenic anti-GAD65 autoantibodies in stiff person syndrome. PLoS One. 2010;5:e10838. [Zimmer J, editor].","DOI":"10.1371\/journal.pone.0010838"},{"key":"10.1007\/s13311-022-01196-w_bib186","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.25414","article-title":"Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders: GAD-Reactive B Cells","volume":"85","author":"Thaler","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib187","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/RHU.0b013e3181e931fa","article-title":"Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab","volume":"16","author":"Bacorro","year":"2010","journal-title":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases"},{"key":"10.1007\/s13311-022-01196-w_bib188","doi-asserted-by":"crossref","unstructured":"Lobo ME, Araujo ML, Tomaz CA, et al. Stiff-person syndrome treated with rituximab. BMJ Case Reports. 2010;2010.","DOI":"10.1136\/bcr.05.2010.3021"},{"key":"10.1007\/s13311-022-01196-w_bib189","first-page":"S20","article-title":"A double-blind, placebo-cotrolled study of rituximab in patients with stiff-person syndrome (SPS)","volume":"66","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib190","doi-asserted-by":"crossref","unstructured":"Zdziarski P. A case of stiff person syndrome: immunomodulatory effect of benzodiazepines: successful rituximab and tizanidine therapy. Medicine. 2015;94:e954.","DOI":"10.1097\/MD.0000000000000954"},{"key":"10.1007\/s13311-022-01196-w_bib191","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1756285615614812","article-title":"Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab","volume":"9","author":"Magira","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-022-01196-w_bib192","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","article-title":"Acetylcholine receptors and myasthenia","volume":"23","author":"Lindstrom","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-022-01196-w_bib193","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01196-w_bib194","doi-asserted-by":"crossref","unstructured":"Cao Y, Amezquita RA, Kleinstein SH, et al. Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-\u03b3, and GM-CSF and diminished IL-10 production. J.I. 2016;196:2075\u20132084.","DOI":"10.4049\/jimmunol.1501339"},{"key":"10.1007\/s13311-022-01196-w_bib195","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1749-6632.1993.tb22873.x","article-title":"High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis","volume":"681","author":"Cohen-Kaminsky","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-022-01196-w_bib196","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0165-5728(97)00161-6","article-title":"Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis","volume":"81","author":"Huang","year":"1998","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib197","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2249.1999.01062.x","article-title":"Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG)","volume":"118","author":"Huang","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib198","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib199","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients","volume":"84","author":"Keung","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01196-w_bib200","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15:113\u201324.","DOI":"10.1038\/s41582-018-0110-z"},{"key":"10.1007\/s13311-022-01196-w_bib201","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib202","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib203","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01196-w_bib204","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib205","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib206","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib207","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01196-w_bib208","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preu\u00dfe","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-022-01196-w_bib209","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734\u20131747. [Longo DL, editor].","DOI":"10.1056\/NEJMra1402225"},{"key":"10.1007\/s13311-022-01196-w_bib210","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1007\/s13311-022-01196-w_bib211","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1007\/s13311-022-01196-w_bib212","first-page":"1009","article-title":"Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature","volume":"27","author":"Rios Fernandez","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-022-01196-w_bib213","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01196-w_bib214","doi-asserted-by":"crossref","unstructured":"Dalakas M. IgG4-mediated neurological autoimmunities: understanding pathogenicity of IgG4, ineffectiveness of IVIg and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm. 2021;9:e1116.","DOI":"10.1212\/NXI.0000000000001116"},{"key":"10.1007\/s13311-022-01196-w_bib215","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021.","DOI":"10.1007\/s13311-021-01108-4"},{"key":"10.1007\/s13311-022-01196-w_bib216","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01196-w_bib217","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib218","doi-asserted-by":"crossref","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, et al. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight. 2017;2:e94263.","DOI":"10.1172\/jci.insight.94263"},{"key":"10.1007\/s13311-022-01196-w_bib219","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","article-title":"The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy","volume":"282","author":"Quan","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01196-w_bib220","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI83840","article-title":"Rituximab does not reset defective early B cell tolerance checkpoints","volume":"126","author":"Chamberlain","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1007\/s13311-022-01196-w_bib221","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01196-w_bib222","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01196-w_bib223","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4049\/jimmunol.1601415","article-title":"Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing","volume":"198","author":"Vander Heiden","year":"2017","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01196-w_bib224","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2013-306958","article-title":"Fcgamma receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy","volume":"85","author":"Stork","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01196-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:58:00Z","timestamp":1761807480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":224,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923010978"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01196-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01196-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}